Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 113.21B |
| Revenue (ttm) | 13.10B |
| Net Income (ttm) | 3.86B |
| Shares Out | 108.37M |
| EPS (ttm) | 33.86 |
| PE Ratio | 30.85 |
| Forward PE | 22.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 358,412 |
| Open | 1,054.00 |
| Previous Close | 1,057.02 |
| Day's Range | 1,030.23 - 1,059.92 |
| 52-Week Range | 688.52 - 1,081.17 |
| Beta | 0.12 |
| Analysts | Buy |
| Price Target | 1,021.42 (-2.22%) |
| Earnings Date | Aug 1, 2024 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2023, REGN's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $1,021.42, which is a decrease of -2.22% from the latest price.
News
The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Invites Impacted Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace...
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK , July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) br...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors ar...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investor...
The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac...
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell lympho...
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2024 financial and operating results on Thursda...
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixen...
The Schall Law Firm Initiates Inquiry Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Investors Who Have Incurred Losses To Establish Communication
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac...
The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors a...
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
Regeneron Pharmaceuticals Inc REGN released multiple ascending dose (MAD) data from a Phase 1 study evaluating garetosmab (anti-activin A) and trevogrumab (anti-myostatin) on body composition in healt...
Ophthalmologists Favor Genentech's Vabysmo and Regeneron's Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
New prescriptions for Vabysmo and Eylea HD outpace reported current brand share, indicating further growth of the brands, according to Spherix Global Insights. New prescriptions for Vabysmo and Eylea ...
The Schall Law Firm Commences Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Establish Communication
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac...
The Schall Law Firm Starts Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Initiate Contact
LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac...
The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Establish Communication
LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac...
The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Contact Them
LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac...
The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Connect
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac...
The Schall Law Firm Has Initiated A Probe Into Allegations Against Regeneron Pharmaceuticals Inc (NASDAQ:REGN) And Urges Investors Who Have Incurred Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac...
New Weight-Loss Drugs and Devices Are Coming This Week
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously ...
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
RBC Capital Markets analyst Brian Abrahams reiterated an Outperform rating on Regeneron Pharmaceuticals, Inc. REGN, raising the price forecast to $1,299 from $1,200.
The Schall Law Firm Has Begun An Investigation Into Claims Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Encourages Investors Who Have Suffered Losses To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac...
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Approval in patients with pJIA weighing 63kg or greater adds to Kevzara's position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalg...